Allarity Therapeutics Net Income
| ALLR Stock | USD 0.93 0.09 10.71% |
As of the 10th of February, Allarity Therapeutics shows the Risk Adjusted Performance of (0.08), mean deviation of 3.64, and Standard Deviation of 4.55. Allarity Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Allarity Therapeutics standard deviation and value at risk to decide if Allarity Therapeutics is priced correctly, providing market reflects its regular price of 0.93 per share. Given that Allarity Therapeutics is a hitting penny stock territory we recommend to closely look at its jensen alpha.
Allarity Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Revenue | Earnings Share 5.75 | Revenue Per Share |
| Last Reported | Projected for Next Year | ||
| Net Loss | -22.1 M | -21 M | |
| Net Loss | -24.2 M | -25.4 M | |
| Net Loss | -22.1 M | -23.2 M | |
| Net Loss | (13.73) | (14.42) | |
| Net Income Per E B T | 0.89 | 0.71 |
Allarity | Net Income | Build AI portfolio with Allarity Stock |
Evaluating Allarity Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Allarity Therapeutics's fundamental strength.
Latest Allarity Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Allarity Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Allarity Therapeutics financial statement analysis. It represents the amount of money remaining after all of Allarity Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Allarity Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Allarity Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (24.52 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Allarity Net Income Regression Statistics
| Arithmetic Mean | (9,145,528) | |
| Coefficient Of Variation | (106.13) | |
| Mean Deviation | 8,522,368 | |
| Median | (4,897,742) | |
| Standard Deviation | 9,706,428 | |
| Sample Variance | 94.2T | |
| Range | 26.6M | |
| R-Value | (0.87) | |
| Mean Square Error | 24.4T | |
| R-Squared | 0.76 | |
| Slope | (1,672,366) | |
| Total Sum of Squares | 1507.4T |
Allarity Net Income History
Other Fundumenentals of Allarity Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Allarity Therapeutics Net Income component correlations
Allarity Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Allarity Therapeutics is extremely important. It helps to project a fair market value of Allarity Stock properly, considering its historical fundamentals such as Net Income. Since Allarity Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Allarity Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Allarity Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Allarity have expansion opportunities? Factors like these will boost the valuation of Allarity Therapeutics. If investors know Allarity will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Allarity Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of Allarity Therapeutics is measured differently than its book value, which is the value of Allarity that is recorded on the company's balance sheet. Investors also form their own opinion of Allarity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allarity Therapeutics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Allarity Therapeutics' market value can be influenced by many factors that don't directly affect Allarity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Allarity Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Allarity Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Allarity Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Allarity Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Allarity Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Allarity Therapeutics.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Allarity Therapeutics on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Allarity Therapeutics or generate 0.0% return on investment in Allarity Therapeutics over 90 days. Allarity Therapeutics is related to or competes with Cingulate, Processa Pharmaceuticals, Briacell Therapeutics, Lexaria Bioscience, Lixte Biotechnology, Kairos Pharma, and Curis. Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics usi... More
Allarity Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Allarity Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Allarity Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 19.54 | |||
| Value At Risk | (7.48) | |||
| Potential Upside | 6.93 |
Allarity Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Allarity Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Allarity Therapeutics' standard deviation. In reality, there are many statistical measures that can use Allarity Therapeutics historical prices to predict the future Allarity Therapeutics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.61) | |||
| Total Risk Alpha | (0.98) | |||
| Treynor Ratio | (0.33) |
Allarity Therapeutics February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.32) | |||
| Mean Deviation | 3.64 | |||
| Coefficient Of Variation | (960.03) | |||
| Standard Deviation | 4.55 | |||
| Variance | 20.7 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.61) | |||
| Total Risk Alpha | (0.98) | |||
| Treynor Ratio | (0.33) | |||
| Maximum Drawdown | 19.54 | |||
| Value At Risk | (7.48) | |||
| Potential Upside | 6.93 | |||
| Skewness | 0.1228 | |||
| Kurtosis | (0.52) |
Allarity Therapeutics Backtested Returns
Allarity Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0858, which signifies that the company had a -0.0858 % return per unit of risk over the last 3 months. Allarity Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Allarity Therapeutics' Standard Deviation of 4.55, risk adjusted performance of (0.08), and Mean Deviation of 3.64 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.46, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Allarity Therapeutics will likely underperform. At this point, Allarity Therapeutics has a negative expected return of -0.4%. Please make sure to confirm Allarity Therapeutics' maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Allarity Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.62 |
Good predictability
Allarity Therapeutics has good predictability. Overlapping area represents the amount of predictability between Allarity Therapeutics time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Allarity Therapeutics price movement. The serial correlation of 0.62 indicates that roughly 62.0% of current Allarity Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.62 | |
| Spearman Rank Test | 0.29 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Allarity Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Allarity Therapeutics reported net income of (24.52 Million). This is 107.18% lower than that of the Biotechnology sector and 135.0% lower than that of the Health Care industry. The net income for all United States stocks is 104.29% higher than that of the company.
Allarity Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Allarity Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Allarity Therapeutics could also be used in its relative valuation, which is a method of valuing Allarity Therapeutics by comparing valuation metrics of similar companies.Allarity Therapeutics is currently under evaluation in net income category among its peers.
Allarity Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Allarity Therapeutics from analyzing Allarity Therapeutics' financial statements. These drivers represent accounts that assess Allarity Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Allarity Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 34.3B | 66.0B | 2.8B | 1.9M | 2.2M | 2.1M | |
| Enterprise Value | 34.3B | 66.0B | 2.8B | (16.3M) | (18.7M) | (17.8M) |
Allarity Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Allarity Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Allarity Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Allarity Therapeutics' value.| Shares | Barclays Plc | 2025-06-30 | 0.0 | Stonepine Capital Management Llc | 2025-03-31 | 0.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 0.0 | Xtx Topco Ltd | 2025-06-30 | 51 K | Geode Capital Management, Llc | 2025-06-30 | 50.6 K | Ubs Group Ag | 2025-06-30 | 48 K | Jane Street Group Llc | 2025-06-30 | 26.4 K | Squarepoint Ops Llc | 2025-06-30 | 14.4 K | Tower Research Capital Llc | 2025-06-30 | 3.1 K | Citigroup Inc | 2025-06-30 | 1.5 K | Bank Of America Corp | 2025-06-30 | 138 |
Allarity Fundamentals
| Return On Equity | -1.51 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | (2.12 M) | ||||
| Shares Outstanding | 14.52 M | ||||
| Shares Owned By Insiders | 2.90 % | ||||
| Shares Owned By Institutions | 3.73 % | ||||
| Number Of Shares Shorted | 253.02 K | ||||
| Price To Book | 1.11 X | ||||
| Gross Profit | (36.35 M) | ||||
| EBITDA | (24.23 M) | ||||
| Net Income | (24.52 M) | ||||
| Cash And Equivalents | 7.73 M | ||||
| Cash Per Share | 0.75 X | ||||
| Total Debt | 1.35 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 0.88 X | ||||
| Book Value Per Share | 0.83 X | ||||
| Cash Flow From Operations | (17.35 M) | ||||
| Short Ratio | 1.21 X | ||||
| Earnings Per Share | 5.75 X | ||||
| Target Price | 9.25 | ||||
| Beta | 0.24 | ||||
| Market Capitalization | 17.28 M | ||||
| Total Asset | 22.65 M | ||||
| Retained Earnings | (118.97 M) | ||||
| Working Capital | 11.5 M | ||||
| Net Asset | 22.65 M |
About Allarity Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Allarity Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Allarity Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Allarity Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Allarity Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allarity Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allarity Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Allarity Stock
The ability to find closely correlated positions to Allarity Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allarity Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allarity Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allarity Therapeutics to buy it.
The correlation of Allarity Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allarity Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allarity Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allarity Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Allarity Stock Analysis
When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.